Ilinpru

Linagliptin, the active ingredient in Ilinpru, is a Dipeptidyl peptidase-4 (DPP-4) inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults by improving blood‑glucose control.

GNH USA supplies Ilinpru as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder affecting glucose regulation. - Type 2 diabetes mellitus: improves glycaemic control when used as monotherapy. - Type 2 diabetes mellitus (adjunct to diet and exercise): lowers HbA1c levels in patients who need additional glucose lowering. - Type 2 diabetes mellitus (combination therapy): can be combined with other oral antidiabetics or insulin to achieve target glucose levels.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Dizziness: occasional light‑headedness, especially on standing. - Gastrointestinal upset: nausea or abdominal discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with vomiting, requiring immediate medical attention. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice.

Before initiating linagliptin therapy, clinicians should consider several safety aspects. - Renal function monitoring: assess baseline and periodic kidney function, especially in patients with chronic kidney disease. - Pancreatitis vigilance: educate patients to report persistent abdominal pain. - Hypersensitivity assessment: discontinue if signs of severe allergic reaction appear. - Elderly caution: start at the recommended dose and monitor for adverse events. - Hepatic impairment: use with caution in patients with liver disease. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Linagliptin may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong P‑gp inhibitors (e.g., itraconazole, clarithromycin): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Insulin or sulfonylureas: combined use can heighten risk of hypoglycaemia.

Moderate Interactions (Monitor Closely):\n- Moderate P‑gp inhibitors (e.g., amiodarone): may modestly raise linagliptin levels. - Diuretics (e.g., thiazides): monitor electrolytes and blood pressure when used together.